Skip to content

Study · Randomized controlled trial · n = 397 · 2017

5 results

Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.

White WB, Myers MG, Jordan R, Lucas J

Journal of hypertension1 Apr 2017Cited by 8 (Europe PMC)

PMID27977473 (opens in a new tab)PMCIDPMC5338879 (opens in a new tab)DOI10.1097/hjh.0000000000001221 (opens in a new tab)PepBankPUB-27977473
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In premenopausal women with female sexual dysfunction, bremelanotide 1.25 mg raised ambulatory systolic blood pressure versus placebo by 2.4 mmHg (P 0.029) and 3.0 mmHg (P 0.076) after two doses 24 h apart, in the 0 to 4-h postdose interval.

    In plain wordsIn premenopausal women, bremelanotide 1.25 mg raised systolic blood pressure slightly more than placebo for a short time after dosing.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    IncreaseAmbulatory systolic blood pressure, 1.25 mg
    Study

    n = 397

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    1.25 mg · subcutaneousAs given in this study (human).

    Measurements

    SBP increase vs placebo
    2.4 mmHg
    1.25 mg, first of two doses
    SBP increase vs placebo
    3 mmHg
    1.25 mg, second of two doses

    Source sentences

    Summary
    Increases in ambulatory SBP relative to placebo of 2.4 and 3.0 mmHg (1.25 mg; P values: 0.029 and 0.076) and 3.1 and 3.2 mmHg (1.75 mg; P values: 0.006 and 0.027), respectively, occurred following two doses, separated by 24 h at the 0 to 4-h postdose interval; peak increases typically lasted less than 15 min.
    1 context sentence
    Summary · context
    We studied the effects of bremelanotide administration on ambulatory BP and heart rate (HR), in a randomized, double-blind, placebo-controlled, and parallel-arm trial of three doses of bremelanotide (0.75, 1.25, and 1.75 mg) in 397 premenopausal women with female sexual dysfunction with normotension…
  2. 02HumanRandomized controlled trialSafety outcome

    In premenopausal women with female sexual dysfunction, bremelanotide 1.75 mg raised ambulatory systolic blood pressure versus placebo in the 0 to 4-h postdose interval after two doses 24 h apart.

    In plain wordsIn premenopausal women, bremelanotide 1.75 mg raised systolic blood pressure slightly more than placebo for a short time after dosing.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    IncreaseAmbulatory systolic blood pressure, 1.75 mg
    Study

    n = 397

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    1.75 mg · subcutaneousAs given in this study (human).

    Measurements

    SBP increase vs placebo
    3.1 mmHg
    1.75 mg, first of two doses
    SBP increase vs placebo
    3.2 mmHg
    1.75 mg, second of two doses

    Source sentences

    Summary
    Increases in ambulatory SBP relative to placebo of 2.4 and 3.0 mmHg (1.25 mg; P values: 0.029 and 0.076) and 3.1 and 3.2 mmHg (1.75 mg; P values: 0.006 and 0.027), respectively, occurred following two doses, separated by 24 h at the 0 to 4-h postdose interval; peak increases typically lasted less than 15 min.
    1 context sentence
    Summary · context
    We studied the effects of bremelanotide administration on ambulatory BP and heart rate (HR), in a randomized, double-blind, placebo-controlled, and parallel-arm trial of three doses of bremelanotide (0.75, 1.25, and 1.75 mg) in 397 premenopausal women with female sexual dysfunction with normotension…
  3. 03HumanRandomized controlled trialSafety outcome

    In premenopausal women with female sexual dysfunction, bremelanotide caused similar increases in ambulatory diastolic blood pressure.

    In plain wordsIn premenopausal women, bremelanotide also raised diastolic blood pressure slightly, to a similar degree as systolic.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    IncreaseAmbulatory diastolic blood pressure
    Study

    n = 397

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Similar increases in the DBP were observed.
    1 context sentence
    Summary · context
    We studied the effects of bremelanotide administration on ambulatory BP and heart rate (HR), in a randomized, double-blind, placebo-controlled, and parallel-arm trial of three doses of bremelanotide (0.75, 1.25, and 1.75 mg) in 397 premenopausal women with female sexual dysfunction with normotension…
  4. 04HumanRandomized controlled trialSafety outcome

    In premenopausal women with female sexual dysfunction, bremelanotide 1.75 mg lowered heart rate during the 0-4-h interval, alongside the blood pressure increases.

    In plain wordsIn premenopausal women, bremelanotide 1.75 mg slowed the heart rate a little in the first hours after dosing.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    DecreaseAmbulatory heart rate, 1.75 mg
    Study

    n = 397

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    1.75 mg · subcutaneousAs given in this study (human).

    Measurements

    Heart rate change
    −4.6 to −4.7 bpm
    1.75 mg, 0-4 h interval

    Source sentences

    Summary
    Increases in BP were accompanied by reductions in HR during the 0-4-h interval for the 1.75-mg dose (-4.6 to -4.7 bpm; P < 0.001).
    1 context sentence
    Summary · context
    We studied the effects of bremelanotide administration on ambulatory BP and heart rate (HR), in a randomized, double-blind, placebo-controlled, and parallel-arm trial of three doses of bremelanotide (0.75, 1.25, and 1.75 mg) in 397 premenopausal women with female sexual dysfunction with normotension…
  5. 05HumanRandomized controlled trialSafety outcome

    In premenopausal women with female sexual dysfunction, Twenty-six participants stopped after randomization because of prespecified blood pressure increases, with similar proportions across the four treatment groups.

    In plain wordsIn premenopausal women, twenty-six stopped because of blood pressure rises, and the share was similar in all four groups, placebo included.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    No significant changeDiscontinuation due to prespecified blood pressure increases
    Study

    n = 397

    Comparator
    Placebo
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    0.75, 1.25 and 1.75 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Twenty-six participants discontinued after randomization due to prespecified increases in BP but the proportions were similar among the four treatment groups.
    1 context sentence
    Summary · context
    We studied the effects of bremelanotide administration on ambulatory BP and heart rate (HR), in a randomized, double-blind, placebo-controlled, and parallel-arm trial of three doses of bremelanotide (0.75, 1.25, and 1.75 mg) in 397 premenopausal women with female sexual dysfunction with normotension…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.